Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients

Since the COVID-19 pandemic started, mesenchymal stromal cells (MSC) appeared as a therapeutic option to reduce the over-activated inflammatory response and promote recovery of lung damage. Most clinical studies use intravenous injection for MSC delivery, raising several concerns of thrombogenic ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Araldi, Rodrigo Pinheiro, Prezoto, Benedito Carlos, Gonzaga, Vivian, Policiquio, Bruna, Mendes, Thais Biude, D’Amélio, Fernanda, Vigerelli, Hugo, Viana, Mariana, Valverde, Cristiane Wenceslau, Pagani, Eduardo, Kerkis, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971080/
https://www.ncbi.nlm.nih.gov/pubmed/36068779
http://dx.doi.org/10.1016/j.biopha.2022.112920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971080/
https://www.ncbi.nlm.nih.gov/pubmed/36068779
http://dx.doi.org/10.1016/j.biopha.2022.112920

Ejemplares similares